CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO).
NCT03813381 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160
Last updated 2023-10-16
Summary
The increasing incidence of Esophageal Adenocarcinoma (EAC) in several Western countries can be primarily ascribed to risk factors such as obesity, chronic gastroesophageal reflux, dietary habits and alcohol intake. Nevertheless, Barrett's Esophagus (BE), remains the main risk factor for EAC. Several studies supports the role played by the gut microbiota on the modulation of metabolic and immunological pathways. An abnormal state of the microbial ecosystem seems to be involved in the promotion and onset of various diseases, including cancer. Recent studies have shown that diet and lifestyle have an important modulatory role as protective or risk factors for oncological diseases. The World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) released a review of the evidence that emerged from published studies in the field of nutrition and cancer prevention and summarized their findings into 10 recommendations. Several studies have also shown that a moderate caloric and/or protein restriction seems to be able to reduce the risk of neoplastic disease development. The primary aim of this study is to evaluate the impact of a lifestyle-oriented intervention on body weight, waist circumference, biomarkers associated with cancer risk, esophageal microbiota composition and adherence to cancer prevention recommendations after 24 months in overweight or obese BE patients.
Methods and analysis: Patients are randomly divided into two arms, a control arm (CA) and an interventional arm (IA). The CA receives information about a correct lifestyle to prevent cancer.
The IA is involved in the two-year program of moderate caloric and protein restriction.
At the time of enrollment, anthropometric measurements will be recorded for each patient and they will be randomized to IA or CA. Blood samples will be obtained from each patient and blood glucose will be determined. Serum metabolic biomarkers will be measured in each serum sample and total proteins will be extracted from fresh frozen esophageal biopsy and will be analyzed to evaluate the insulin signal pathway.
To assess esophageal microbiota profiling, total genomic DNA (gDNA) will be extracted from matched fresh frozen biopsy.
In order to determine a score of adherence to cancer prevention recommendations, participants will be asked to complete a self-administrated questionnaire reflecting WCRF/AICR recommendations.
All the measurements will also occur at the end point, after two years from the enrollment.
Conditions
- Barrett's Esophagus
- Overweight and Obesity
Interventions
- BEHAVIORAL
-
Calorie and protein restriction diet
Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food. Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session. Each patient in the IA will be involved in at least three 4-hour cooking classes. Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention.
Sponsors & Collaborators
-
Istituto Oncologico Veneto IRCCS
lead OTHER
Principal Investigators
-
Stefano Realdon, MD, PhD · Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-30
- Primary Completion
- 2021-06-30
- Completion
- 2021-12-31
More Related Trials
-
The Detection of Barrett's Esophagus by Gastrointestinal Endoscopy Prevents Esophageal Carcinoma in Morbid Obese After Sleeve Gastrectomy
NCT03596411 ·Status: COMPLETED
-
Protein Need and Interest of " Quick Proteins " to the Obese Subject Operated by Bariatric Surgery (BIBOP)
NCT01249326 ·Status: COMPLETED ·Phase: NA
-
Protein Digestion After Bariatric Surgery in Older Adults
NCT06076187 ·Status: COMPLETED
-
Effect of Protein Supplementation and a Structured Exercise Program on Muscle in Women After Bariatric Surgery.
NCT04771377 ·Status: COMPLETED ·Phase: NA
-
Pre-operative Very Low-calorie Protein-based Versus Hypocaloric Enteral Nutrition
NCT02418975 ·Status: UNKNOWN ·Phase: NA
-
Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)
NCT04605081 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Naltrexone/Bupropion With or Without Very Low Calorie Ketogenic Diet for Weight Regain After Bariatric Surgery
NCT06881485 ·Status: RECRUITING ·Phase: NA
-
Controlled Trial Evaluating the Efficacy of Protein Supplementation in the Short Term After Bariatric Surgery
NCT02712086 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of the Mediterranean Diet on Weight Loss After Endoscopic Bariatric Treatmen
NCT04738656 ·Status: COMPLETED
-
Prevention of Postoperative Nausea and Vomiting After Bariatric Surgery
NCT04644445 ·Status: UNKNOWN ·Phase: NA
-
Oral Health in Bariatric Patients
NCT03516201 ·Status: COMPLETED
-
Effects of Bariatric Surgery on Cardiovascular Risk Profile in Relation to Inflammatory Parameters: Endothelial Phenotyping and Analysis of the Cross-talk Between Adipose Tissue and Endothelium
NCT07131605 ·Status: RECRUITING ·Phase: NA
-
Bariatric Surgery and Epicardial Adipose Tissue: a MRI Study
NCT03273621 ·Status: COMPLETED
-
Alternative Healthcare Delivery Strategies to Prevent Weight Regain After Bariatric Surgery
NCT05946187 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Post-Bariatric Weight Regain Behavioral Intervention
NCT03564392 ·Status: COMPLETED ·Phase: NA
-
The Role of Nutrition in Muscle Function of Bariatric Surgery Patients
NCT06680492 ·Status: RECRUITING
-
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
NCT04599478 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Sleeve Gastrectomy With Cruroplasty and Omental Rape for Treatment of Morbid Obesity With Reflux Disease
NCT05590208 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Liquid Versus Powder Protein Supplementation to Optimize Protein Intake After Bariatric Surgery
NCT06267677 ·Status: COMPLETED ·Phase: NA
-
Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
NCT00951093 ·Status: COMPLETED
-
Evaluation of Protein Intake and Micronutrient Supplementation After Bariatric Surgery
NCT04587076 ·Status: COMPLETED
-
Transoral Fundoplication Prior to Sleeve Gastrectomy Versus RNY Gastric Bypass on GERD Symptoms in Bariatric Patients
NCT05365087 ·Status: ACTIVE_NOT_RECRUITING
-
Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery
NCT03391401 ·Status: COMPLETED
-
Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome
NCT05408728 ·Status: ENROLLING_BY_INVITATION
-
Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study
NCT04587310 ·Status: COMPLETED